Key facts
- This page summarizes David Shook's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jun 2026, 16:07.
David Shook - 10 Jun 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- LYEL
- Reported as of
- 10 Jun 2026
- Net transaction value
- -$24,989
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2026, 16:07:50 UTC
- Prior SEC filing
- 11 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Meltz, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Shook filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 11 Jun 2026.
Change
- Previous filing in this sequence was filed on 11 Feb 2026.
- Current net transaction value: -$24,989.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001959742
Primary reporting owner
Shook David
- Relationship
- Chief Medical Officer
- Address
- C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
- Signature
- /s/ Mark Meltz, Attorney-in-Fact
- Signature date
- 11 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LYEL
transaction
Common Stock
Sale
- Transaction value
- $24,989
- Shares
- -1,977
- Change %
- -8.6%
- Price
- $12.64
- Shares after
- 20,923
- Date
- 10 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Footnote F2
Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.